Cha2ds2vasc Calculator
Estimate your cha2ds2vasc with our free cardiovascular system calculator. See reference ranges, risk factors, and next-step guidance.
Calculator
Adjust values & calculateNo antithrombotic therapy recommended. The stroke risk is very low and anticoagulation is not indicated for patients with a score of 0.
Formula
C = Congestive heart failure (1 pt), H = Hypertension (1 pt), A2 = Age 75+ (2 pts), D = Diabetes (1 pt), S2 = Stroke/TIA/thromboembolism (2 pts), V = Vascular disease (1 pt), A = Age 65-74 (1 pt), Sc = Sex category female (1 pt). Score determines stroke risk and anticoagulation recommendation.
Last reviewed: January 2026
Worked Examples
Example 1: Low-Risk Male Patient
Example 2: High-Risk Female Patient
Background & Theory
The Cha2ds2vasc Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/m²), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 × weight in kg) + (6.25 × height in cm) − (5 × age) ± sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.
History
The history behind the Cha2ds2vasc Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.
Frequently Asked Questions
Sources & References
- 1Lip GYH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. Chest. 2010;137(2):263-272.
- 2January CT, et al. 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.
- 3Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498.
Formula
CHA2DS2-VASc = C + H + A2 + D + S2 + V + A + Sc (max 9)
C = Congestive heart failure (1 pt), H = Hypertension (1 pt), A2 = Age 75+ (2 pts), D = Diabetes (1 pt), S2 = Stroke/TIA/thromboembolism (2 pts), V = Vascular disease (1 pt), A = Age 65-74 (1 pt), Sc = Sex category female (1 pt). Score determines stroke risk and anticoagulation recommendation.
Worked Examples
Example 1: Low-Risk Male Patient
Problem: A 55-year-old male with newly diagnosed paroxysmal atrial fibrillation. No hypertension, diabetes, heart failure, vascular disease, or prior stroke. Calculate CHA2DS2-VASc score.
Solution: C (CHF): 0\nH (Hypertension): 0\nA2 (Age >=75): 0\nD (Diabetes): 0\nS2 (Stroke/TIA): 0\nV (Vascular disease): 0\nA (Age 65-74): 0\nSc (Sex - male): 0\nTotal CHA2DS2-VASc = 0
Result: Score: 0 (Low Risk, ~0% annual stroke rate). No anticoagulation recommended.
Example 2: High-Risk Female Patient
Problem: A 78-year-old female with atrial fibrillation, hypertension, type 2 diabetes, prior TIA, and history of MI. Calculate CHA2DS2-VASc score.
Solution: C (CHF): 0\nH (Hypertension): +1\nA2 (Age >=75): +2\nD (Diabetes): +1\nS2 (Prior TIA): +2\nV (Prior MI): +1\nA (Age 65-74): 0 (superseded by age >=75)\nSc (Female): +1\nTotal CHA2DS2-VASc = 8
Result: Score: 8 (High Risk, ~6.7% annual stroke rate). Oral anticoagulation with DOAC strongly recommended.
Frequently Asked Questions
What is the CHA2DS2-VASc score and what is it used for?
The CHA2DS2-VASc score is a clinical prediction tool used to estimate the annual risk of stroke in patients with non-valvular atrial fibrillation. It was developed as an improvement over the original CHADS2 score to better identify truly low-risk patients who do not need anticoagulation. The acronym represents Congestive heart failure (1 point), Hypertension (1 point), Age 75 or older (2 points), Diabetes mellitus (1 point), Stroke/TIA/thromboembolism (2 points), Vascular disease (1 point), Age 65-74 (1 point), and Sex category female (1 point). The maximum score is 9. It is the most widely recommended stroke risk stratification tool in current international guidelines for atrial fibrillation management.
How does the CHA2DS2-VASc score guide anticoagulation therapy?
The CHA2DS2-VASc score directly determines whether oral anticoagulation should be initiated in patients with atrial fibrillation. According to current ESC and AHA/ACC guidelines, a score of 0 in men (or 1 in women where the only point is female sex) indicates low stroke risk, and no antithrombotic therapy is recommended. A score of 1 in men represents a zone where anticoagulation should be considered based on individual assessment. A score of 2 or higher in men (3 or higher in women) strongly recommends oral anticoagulation, preferably with a direct oral anticoagulant (DOAC) such as apixaban, rivaroxaban, dabigatran, or edoxaban rather than warfarin. Aspirin alone is no longer recommended for stroke prevention in atrial fibrillation as it provides minimal benefit with significant bleeding risk.
Why does female sex receive a point in the CHA2DS2-VASc score?
Female sex was included in the CHA2DS2-VASc score because epidemiological studies showed that women with atrial fibrillation have a higher relative risk of stroke compared to men, particularly in older age groups and when other risk factors are present. However, the role of female sex as an independent risk factor has been debated extensively. Current guidelines clarify that female sex is a stroke risk modifier rather than an independent risk factor, meaning it increases risk only when other risk factors are present. A woman with atrial fibrillation and no other risk factors (CHA2DS2-VASc of 1 based on sex alone) is considered low risk and does not require anticoagulation. This distinction is important to avoid unnecessary treatment in young, otherwise healthy women with lone atrial fibrillation.
What qualifies as vascular disease in the CHA2DS2-VASc score?
Vascular disease in the CHA2DS2-VASc score encompasses several conditions affecting the arterial system. Specifically, it includes prior myocardial infarction, peripheral arterial disease (PAD) documented by ankle-brachial index, angiography, or prior revascularization, and aortic plaque identified on imaging. Coronary artery disease diagnosed by angiography showing significant stenosis also qualifies, even without prior myocardial infarction. Some studies have also included carotid artery disease with significant stenosis. The rationale for including vascular disease is that these conditions share common pathophysiology with cardioembolic stroke including endothelial dysfunction, atherosclerosis, and prothrombotic states. Simple coronary artery disease risk factors such as hyperlipidemia alone do not qualify as vascular disease for this scoring system.
How accurate is the CHA2DS2-VASc score at predicting stroke?
The CHA2DS2-VASc score has moderate discriminative ability for predicting stroke, with C-statistics typically ranging from 0.55 to 0.70 across validation studies. Its primary strength lies in its excellent ability to identify truly low-risk patients (score of 0) who have annual stroke rates below 1 percent, making it highly effective as a screening tool for anticoagulation decisions. The score performs less well at discriminating between moderate and high-risk categories, as actual stroke rates do not increase linearly with each point. Large validation studies including over 170,000 patients have confirmed that the score reliably categorizes patients into clinically meaningful risk groups. However, individual patient risk can vary based on factors not captured in the score, including left atrial size, atrial fibrillation burden, and biomarker levels.
What is the difference between CHADS2 and CHA2DS2-VASc scores?
The original CHADS2 score included only five risk factors: Congestive heart failure (1 point), Hypertension (1 point), Age over 75 (1 point), Diabetes (1 point), and Stroke/TIA (2 points), with a maximum of 6 points. The CHA2DS2-VASc score expanded on this by adding three additional risk factors: vascular disease (1 point), age 65-74 (1 point), and female sex (1 point), while also increasing the age over 75 component to 2 points, creating a maximum score of 9. The key improvement was the ability to reclassify patients in the CHADS2 score of 0 or 1 categories, where many patients were found to have annual stroke rates exceeding 1 percent when CHA2DS2-VASc factors were considered. This reduced the intermediate risk category where treatment decisions were unclear.
References
- Lip GYH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. Chest. 2010;137(2):263-272.
- January CT, et al. 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498.
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy